March 31, 2023 00:33 ET – Dosis al primer paciente de VIRAGE, un ensayo clínico de fase 2b de VCN-01 administrado sistémicamente en combinación con quimioterapia en el adenocarcinoma ductal pancreático – – Dosis al primer paciente del ensayo de fase 1 patrocinado por investigadores de VCN-01 en pacientes con tumores cerebrales – – Presentación […]
March 30, 2023 08:00 ET – Dosed the first patient in VIRAGE, a Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma – – Dosed the first patient in the investigator sponsored Phase 1 clinical trial of VCN-01 for patients with brain tumors – – Presented positive safety
February 16, 2023 12:05 ET – Data presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR – – Analysis of patients receiving meropenem suggest that SYN-004 is well-tolerated with HCT and was not observed in blood samples from the majority of the evaluable patients – ROCKVILLE, Md., Feb. 16,
February 16, 2023 12:05 ET – Datos presentados en los Tandem Meetings 2023: Reuniones sobre trasplantes y terapias celulares de la ASTCT y el CIBMTR – – Los análisis de los pacientes que recibieron meropenem sugieren que SYN-004 se tolera bien con HCT y no se observó en las muestras de sangre de la mayoría
Want to learn more? We’d love to hear from you. US Headquarters 9605 Medical Center Dr. Suite 270 Rockville, MD 20850 European Office Theriva™ Biologics SL Carrer Torrent de Can Ninou, naus 5-6 08150 – Parets del Vallès (Barcelona) Spain Email info@therivabio.com
November 03, 2022 08:00 ET – Initiation of Cohort 2 Follows a Positive Review of Safety and Pharmacokinetic (PK) Data from Cohort 1 by an Independent Data and Safety Monitoring Committee – – Cohort 2 Patient Dosing Highlights Momentum Across the Theriva Oncology-Focused Clinical Pipeline – ROCKVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) — Theriva
September 27, 2022 08:00 ET – The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended that the study may proceed to enroll patients into Cohort 2 – ROCKVILLE, Md., Sept. 27, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat
-Treatment with VCN-01 in combination with durvalumab demonstrated an acceptable safety profile and encouraging biological activity- ROCKVILLE, Md., Sept. 05, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced a presentation of initial data from a
-Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1, 2022 of $53.5 million, including the additional $3 million in gross proceeds from convertible preferred financing extends funding for business operations into Q1 2024- -Conference call and webcast to be held today at 8:30 a.m. ET- ROCKVILLE, Md., Aug. 11,
ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Thursday, August 11, 2022, at 8:30 a.m. ET to discuss its financial results for
